natgillin/translations-raw huggingface dataset:
Respons var defineret som: ≥50 % reduktion i summen af SEGA-volumen i forhold til baseline, plus ingen utvetydig forværring af ikke-mål-SEGA-læsioner, plus fravær af ny SEGA ≥1 cm for den længste diameter, plus ingen ny eller forværret hydrocephalus
Response was defined as: ≥50% reduction in the sum of SEGA volume relative to baseline, plus no unequivocal worsening of non-target SEGA lesions, plus absence of new SEGA ≥1 cm in longest diameter, plus no new or worsening hydrocephalus
Respons var forbundet med INI-mutationsforløbet som vist i tabel 5.
Response was associated with baseline INI mutation pathway, as shown in Table 5.
Respons ved afslutnin g af behand- ling
Response at End of Treatment
Respons ved afslutning af
End of treatment response
Respons ved afslutning af behand- ling
Response at End of Treatment
Respons ved afslutning af behandlingen
End of treatment response
Respons ved afsluttet
Response at end of
Respons ved afsluttet behandling
End of treatment response
Respons ved baseline-hiv-1- RNA < 100.000 kopier/ml
Response by Baseline HIV-1 RNA
Respons ved baseline-hiv-1- RNA < 100.000 kopier/ml
Response by Baseline HIV-1 RNA <100,000 c/mL
Respons ved baseline-hiv-1- RNA ≥ 100.000 kopier/ml
Response by Baseline HIV-1 RNA
Respons ved baseline-hiv-1- RNA ≥ 100.000 kopier/ml
Response by Baseline HIV-1 RNA 100,000 c/mL
respons ved dosisjustering (se
Medicinal product by therapeutic areas (dose)
Respons ved Positiv behandling Vedvarend prædiktiv s uge e respons værdi
Response at Positive treatment Sustained predictive week response value
Respons ved Positiv behandlingsu Vedvarend prædikti ge e respons v værdi
Response at Positive treatment Sustained predictive week response value
Respons ved uge 12
Response by week 12
Respons, remission og slimhindeheling i studie UC-II (Procent patienter)
Response, Remission and Mucosal Healing in Study UC-II (Percent of Patients)
Respons-
Response
Respons- incidens
Response Rate
Respons- kategori
Response category
Respons- parameter
Response
Respons- vurdering baseredes på et sammensat endepunkt defineret som ovenfor.
Response assessment was based on a composite endpoint defined as above.
Respons-hyppigheden var ens for de to køn.
The response rate was similar for both genders.
respons.
ANTIDEPRESSANTS
Responsa
Responsea
Responsa, n (%)
N = 170
Response rate (95 % CI)
Response rate (95% CI)
Response rate (95 %CI)
Response rate (95% CI)
Responsen blev defineret som varig, når patientens blodpladeantal var over 50 mio. pr. ml i mindst seks af de sidste otte uger af 24-ugersbehandlingen, og uden at der var behov for yderligere lægemidler mod ITP.
This was classified as the patient’s platelet counts being above 50 million per millilitre for at least six of the last eight weeks of the 24-week treatment period, without the need for any other medicines for ITP.
Responsen på behandlingen blev bedømt ved hjælp af kropsscanning og patienternes kliniske data.
Response to treatment was assessed using body scans and patients’ clinical data.
Responsen på behandlingen blev målt på reduktionen i blodets indhold af proteinen IgM, som findes i store mængder i blodet hos patienter med Waldenströms sygdom.
Response to treatment was measured as a reduction in the blood levels of the protein IgM, which is present in high levels in patients with Waldenström’s disease.
Responsen på behandlingen blev målt som fuldstændigt eller delvist fravær af tegn på kræft.
Response to treatment was measured as complete or partial lack of signs of cancer.
Responsen på behandlingen blev vurderet ved at iagttage patienternes symptomer, antallet af lymfocytter i deres blod, resultater af blodprøver og knoglemarvsprøver samt størrelsen på deres lymfeknuder, lever og milt.
The response to treatment was assessed by looking at the patients’ symptoms, the number of lymphocytes in their blood, results of blood and bone marrow tests and the size of their lymph nodes, liver and spleen.
Responser er sammenfattet i tabel 5.
Responses are summarised in Table 5.
Responset blev målt ved brug af ACR Pedi 30, defineret som 30 % forbedring af mindst tre af seks og 30 % forværring af højst en af seks JRA kernekriterier, inkl. tælling af aktive led, begrænsning af motion, lægens og patientens/forældrenes almene bedømmelse, funktionsbedømmelse og erytrocyt- sedimentationsrate (ESR).
Responses were measured using ACR Pedi 30 , defined as  30% improvement in at least three of six and  30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR).
Responset blev målt ved brug af ACR Pedi 30, defineret som 30 % forbedring af mindst tre af seks og 30 % forværring af højst en af seks JRA kernekriterier, inkl. tælling af aktive led, begrænsning af motion, lægens og patientens/forældrenes almene bedømmelse, funktionsbedømmelse og erytrocyt- sedimentationsrate (ESR).
Responses were measured using the ACR Pedi 30 ), defined as  30% improvement in at least three of six and  30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR).
Responset blev målt ved brug af ACR Pedi 30, defineret som 30 % forbedring af mindst tre af seks og 30 % forværring af højst en af seks JRA kernekriterier, inkl. tælling af aktive led, begrænsning af motion, lægens og patientens/forældrenes almene bedømmelse, funktionsbedømmelse og erytrocyt- sedimentationsrate (ESR).
Responses were measured using the ACR Pedi 30 , defined as  30% improvement in at least three of six and  30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR).
Responset blev målt ved brug af ACR Pedi 30, defineret som 30 % forbedring af mindst tre af seks og 30 % forværring af højst en af seks JRA kernekriterier, inkl. tælling af aktive led, begrænsning af motion, lægens og patientens/forældrenes almene bedømmelse, funktionsbedømmelse og erytrocyt- sedimentationsrate (ESR).
Responses were measured using the ACR Pedi 30, defined as  30% improvement in at least three of six and  30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR).
Responset blev målt ved brug af ACR Pedi 30, defineret som 30 % forbedring af mindst tre af seks og 30 % forværring af højst en af seks JRA- kernekriterier, inkl. tælling af aktive led, bevægelsesindskrænkning, lægens og patientens/forældrenes overordnede bedømmelse, funktionsbedømmelse og erytrocyt-sedimentationshastighed (ESR).
Responses were measured using the ACR Pedi 30, defined as  30% improvement in at least three of six and  30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR).
Responset på behandlingen, kan ikke i tilstrækkelig grad vurderes, før de lokale hudreaktioner er forsvundet.
Response to treatment cannot be adequately assessed until resolution of local skin reactions.
Responset på serotype 6A, som er unikt for Prevenar 13, blev vurderet ved demonstration af en firdobbelt stigning i den specifikke OPA-titer i forhold til niveauet før immunisering.
The response to serotype 6A, which is unique to Prevenar 13, was assessed by demonstration of a 4-fold increase in the specific OPA titer above pre- immunised levels.
Responset på vaccination kan være nedsat, når B-cellerne er depleterede.
The response to vaccination could be impaired when B cells are depleted.
Responset var imidlertid ikke livstruende, og hundene kom sig hurtigt efter behandlingens ophør.
However, the response was not life-threatening and the dogs recovered quickly upon discontinuation of treatment.
Responsfrekvens +/- SE (%)
Response Rate +/- SE (%)
Responshyppigheden, der er baseret på NC = F analyse af den procentdel af patienter med plasma hiv-RNA  400 kopier/ml efter 48 uger var 60% (95%, C.I. 47, 72) og 53% (C.I. 40, 66) baseret på procentdelen af patienter med plasma hiv-RNA  50 kopier/ml.
The response rate, based on the NC = F analysis of the percentage of patients with plasma HIV-RNA < 400 copies/ml at 48 weeks was 60 % (95 %, C.I. 47, 72), and 53 % (C.I. 40, 66) based on percentage of patients with plasma HIV-RNA < 50 copies/ml.
Responshyppigheden, der er baseret på NC = F analyse af den procentdel af patienter med plasma hiv-RNA  400 kopier/ml efter 48 uger var 60% (95%, C.I. 47, 72) og 53% (C.I. 40, 66), der er baseret på procentdelen af patienter med plasma hiv-RNA  50 kopier/ml.
The response rate, based on the NC = F analysis of the percentage of patients with plasma HIV-RNA < 400 copies/ml at 48 weeks was 60 % (95 %, C.I. 47, 72), and 53 % (C.I. 40, 66) based on percentage of patients with plasma HIV-RNA < 50 copies/ml.
Responshyppigheder (NC = F**a) Plasma hiv-RNA
Responder rates (NC = Fa) Plasma HIV-RNA
Responshyppigheder (NC = Fa)
Responder rates (NC = Fa)
Responsincidens
Response Rate
Responskategori (follikulært lymfom)*
Response category (follicular lymphoma)* CR
Responsrate
Response rate
Responsrate (%)
Response rate (%) (95% CI)
Responsrate (%) (95 % CI)
95% CI for median
Responsrate (%) (95 % CI)
Response rate (%)
Responsrate (%) (95 % CI)
Response rate (%) (95% CI)
Responsrate (%) (95 %-CI)
Response rate (%) (95 % CI)
Responsrate (%) (95 %-CI)
Response rate (%) (95% CI)
Responsrate (%) (95 %-CI)
Response rate (%)(95 % CI)
Responsrate (%) (95 %-CI)
The overall response rate was 14.1 %.
Responsrate (CR+PR)
Response Rate (CR+PR)
Responsrate (konfidensintervaller)*
Response Rate (confidence intervals)
Responsrate (vurderet af investigator)a (95 % CI)
Response rate (investigator assessed)a (95% CI)
Responsrate hos patienter med kromosomabnormitet
Response rate in patients with chromosomal abnormality
Responsrate hos patienter, der har fået forudgående behandling med rituximab
Response rate in patients with prior rituximab therapy
Responsrate i alt (CR+PR) (%)
Overall response rate (CR+PR) (%)
Responsrate i alt (CR+PR) (%)
Overall response rate (CR+PR) (%) p-value
Responsrate og CR-rater er analyseret med χ2-test.
Response rate and CR rates analysed using Chi--squared Test.
Responsrate og CR-rater er analyseret med χ2-test.
Response rate and CR rates analysed using Chi-squared Test.
Responsrate på ≥ 60% bedring i mEASI (Primær parameter)§§
Response rate of ≥ 60% improvement in mEASI (Primary
Responsrate ved behandlingsafslutning
End of treatment response rate
Responsrate, %
Response Rate,
Responsrate2
50.0
Responsrate2
57.1
Responsrate2
68.2
Responsraten for andre akutte myelogene leukæmi-undertyper over for TRISENOX er ikke undersøgt.
The response rate of other acute myelogenous leukaemia subtypes to TRISENOX has not been examined.
Responsraten for topotecan i det kombinerede program for småcellet lungecancer (n=480) for patienter med recidiverende sygdom efter første linie behandling var 20,2 %.
The response rate to topotecan in the combined small cell lung cancer programme (n = 480) for patients with relapsed disease sensitive to first-line therapy, was 20.2 %.
Responsraten for topotecan i det kombinerede program for småcellet lungecancer(n = 480) for patienter med recidiverende sygdom efter førstelinjebehandling var 20,2 %.
The response rate to topotecan in the combined small cell lung cancer programme (n = 480) for patients with relapsed disease sensitive to first-line therapy, was 20.2 %.
Responsraten for topotecan var 20,2 % i det kombinerede program for småcellet lungecancer (n=480) for patienter med recidiverende sygdom efter 1. linje-behandling.
The response rate to topotecan in the combined small cell lung cancer programme (n=480) for patients with relapsed disease sensitive to first-line therapy, was 20.2 %.
Responsraten for topotecan var 20,2 % i det kombinerede program for småcellet lungecancer (n=480) for patienter med recidiverende sygdom efter 1. linje-behandling.
The response rate to topotecan in the combined small cell lung cancer programme (n=480) for patients with relapsed disease sensitive to first-line therapy, was 20.2%.
Responsraten hos disse patienter var cirka 52 %.
The response rate in these patients was about 52 %.
Responsraten i 0,1% tacrolimusgruppen (71,6%) var signifikant højere end den i gruppen med lokal kortikosteroid behandling (50,8%,
The response rate in the 0.1% tacrolimus group (71.6%) was significantly higher than that in the topical corticosteroid based treatment group (50.8%; p<0.001; Table 1).
Responsraten var højest for de patienter, som skiftede NRTI’ere.
Responder rates were highest in patients who switched NRTIs.
Responsraten, baseret på den centrale reviewers vurdering, var 35 % (13 CR og 43 PR) for intent-to- treat populationen (ITT) n=162.
Response rate, based on the central reviewer assessment, was 35 % (13 CR and 43 PR) for the intent-to-treat population (ITT) n=162.
Responsrater efter tilføjelse af perampanel ved faste doser var mindre, hvis patienterne fik samtidige CYP3A-enzyminducerende antiepileptika (carbamazepin, phenytoin, oxcarbazepin) sammenlignet med responsrater hos patienter, der fik samtidige ikke-enzyminducerende antiepileptika.
Response rates after addition of perampanel at fixed doses were less when patients received concomitant CYP3A enzyme-inducing anti-epileptic medicinal products (carbamazepine, phenytoin, oxcarbazepine) as compared to response rates in patient who received concomitant non-enzyme– inducing anti-epileptic medicinal products.
Responsrater er vist i tabel 10.
Response rates are presented in Table 10.
Responsrater for tipranavir med ritonavir i RESIST-studierne blev vurderet ud fra baseline tipranavir genotype og fænotype.
Tipranavir with ritonavir response rates in the RESIST studies were assessed by baseline tipranavir genotype and phenotype.
Responsraterne for de to behandlingsarme er anført i tabel 10.
The rates of response for the two treatment arms are reported in Table 10.
Responsraterne for evnen til at opnå og vedligeholde en erektion var 47% og 37% for 10 mg og 48% og 34% for 20 mg vardenafil sammenlignet med 22% og 10% for placebo for patienter som gennemførte tre måneders behandling.
The response rates for the ability to obtain and maintain an erection was 47% and 37% on 10 mg and 48% and 34% on 20 mg vardenafil compared to 22% and 10% on placebo for patients who completed three months treatment.
Responsraterne for evnen til at opnå og vedligeholde en erektion var 47% og 37% for 10 mg og 48% og 34% for 20 mg vardenafil sammenlignet med 22% og 10% for placebo for patienter, som gennemførte tre måneders behandling.
The response rates for the ability to obtain and maintain an erection was 47% and 37% on 10 mg and 48% and 34% on 20 mg vardenafil compared to 22% and 10% on placebo for patients who completed three months treatment.
Responsraterne for evnen til at opnå og vedligeholde en erektion var 61% og 49% for 10 mg og 64% og 54% for 20 mg vardenafil sammenlignet med 36% og 23% for placebo for patienter som gennemførte tre måneders behandling.
The response rates for the ability to obtain and maintain an erection was 61% and 49% on 10 mg and 64% and 54% on 20 mg vardenafil compared to 36% and 23% on placebo for patients who completed three months treatment.
Responsraterne for evnen til at opnå og vedligeholde en erektion var 61% og 49% for 10 mg og 64% og 54% for 20 mg vardenafil sammenlignet med 36% og 23% for placebo for patienter, som gennemførte tre måneders behandling.
The response rates for the ability to obtain and maintain an erection was 61% and 49% on 10 mg and 64% and 54% on 20 mg vardenafil compared to 36% and 23% on placebo for patients who completed three months treatment.
Responsraterne for pertussis var de samme som for kontrolvaccinen for alle pertussis-antigener efter booster-dosen.
Pertussis response rates were similar to the control vaccine for all pertussis antigens after the booster dose.
Responsraterne i slutningen af periode A, i slutningen af periode B og efter 5 års eksponering i periode C er opsummeret i Tabel 8.
Response rates at the end of Period A, at the end of Period B and after 5 years exposure in Period C are summarized in Table 8:
Responsraterne ifølge den samlede vurdering af de fem kliniske hudsymptomer var henholdsvis 36 % og 27 %.
The response rates according to the 5 skin scores were 36% and 27%, respectively.
Responsraterne var ens i begge behandlingsarme, med en overordnet responsrate på 80,7 % (95 % konfidensinterval: 70,9; 88,3) og 85,2 % (95 % konfidensinterval: 76,1; 91,9) i henholdsvis MabThera intravenøs og MabThera subkutan behandlingsarmen.
Response rates were similar in each arm, with an overall response rate of 80.7% (95% CI: 70.9; 88.3) and 85.2% (95% CI: 76.1; 91.9) in the MabThera intravenous and subcutaneous arms, respectively.
Responsraterne var statistisk set signifikant højere med Thymanax sammenlignet med placebo.
Response rates were statistically significantly higher with Thymanax compared with placebo.
Responsraterne var statistisk set signifikant højere med Valdoxan sammenlignet med placebo.
Response rates were statistically significantly higher with Valdoxan compared with placebo.
Responstype
Response type
Responsvarighed
Durability of response
Responsvarighed
Duration of Response
Responsvarighed
Response duration
Responsvarighed (DoR)3
Duration of Response (DoR)3
Responsvarighed (vurderet af en uafhængig komité)
Duration of response (DOR) (IRC- assessed)
Responsvarighed*
Duration of response
Responsvarighed, mediana [95 % CI] (uger)
Duration of Response, mediana [95% CI] (weeks)
Responsvarighedb [median (95% CI)] uger
Duration of Responseb [median (95% CI)] weeks
Responsvarigheden
Duration of response
Responsvarigheden var 16 uger (konfidensinterval: 13, 19 uger), og tiden til den næste CLL-behandling var 52,4 uger (konfidensinterval: 36,9 - kan ikke estimeres).
The duration of response was 16 weeks (CI: 13, 19) and the time to next CLL therapy was 52.4 weeks (CI: 36.9 – non-estimable).
Responsvarigheden var 16 uger (konfidensinterval: 13, 19 uger), og tiden til den næste CLL-behandling var 52,4 uger (konfidensinterval: 36,9 - kan ikke estimeres).
The duration of response was 16 weeks (CI: 13.3, 19) and the time to next CLL therapy was 52.4 weeks (CI: 36.9 – non-estimable).
Responsvarighed§
Response Duration§
Responsvarighed§,#,Þ
Response duration§,#,Þ
Responsvarighed§,#,ß
Response duration§,#,ß
Responsvarighed‡
Response duration
Respreeza 1000 mg pulver og solvens til infusionsvæske, opløsning Human alfa-1-proteinasehæmmer
Respreeza 1,000 mg powder and solvent for solution for infusion Human alpha1-proteinase inhibitor
Respreeza 1000 mg pulver og solvens til infusionsvæske, opløsning.
Respreeza 1,000 mg powder and solvent for solution for infusion.
Respreeza 1000 mg pulver til infusionsvæske, opløsning Human alfa-1-proteinasehæmmer
Respreeza 1,000 mg powder for solution for infusion Human alpha1-proteinase inhibitor
Respreeza er et lægemiddel, der anvendes hos voksne med den arvelige sygdom alpha1- proteinaseinhibitormangel, der kan medføre lungeproblemer såsom voksende stakåndethed, og som også kan påvirke leveren.
Respreeza is a medicine used in adults with alpha1-proteinase inhibitor deficiency, an inherited disorder that can cause lung problems such as increasing shortness of breath and which may also affect the liver.
Respreeza er fremstillet ud fra humant blodplasma (den flydende del af blodet, efter blodlegemerne er fjernet).
Respreeza is made from human blood plasma (this is the liquid part of the blood with the blood cells removed).
Respreeza indeholder 1,9 mg natrium pr. ml infusionsvæske.
This medicine contains 1.9 mg sodium per ml of reconstituted solution.
Respreezas sikkerhed og virkning blev evalueret i et randomiseret, dobbeltblindet, placebokontrolleret multicenterstudie (RAPID), efterfulgt af en toårig forlængelse af studiet med åben behandling (RAPID-forlængelsesstudiet).
The safety and efficacy of Respreeza was evaluated in a randomized, double-blind, placebo- controlled, multi-center study (RAPID) followed by a 2-year open-label extension study (RAPID extension study).
Rest- markør
Marker residue
Restdosis- skala
Residual scale
Rester af delte tabletter bør opbevares i den originale blisterpakning.
Partially used tablets should be stored in the original blister.
Rester af delte tabletter bør opbevares i det originale glas.
Partially used tablets should be stored in the original bottle.
Rester af delte tabletter bør opbevares i det originale originale glas.
Partially used tablets should be stored in the original bottle.
Rester af delvist brugte tabletter bør opbevares i den originale blisterpakning.
Store partially used tablets in the original blister.
Rester af delvist brugte tabletter bør opbevares i det originale glas
Store partially used tablets in the original bottle.
Rester af delvist brugte tabletter skal anvendes inden for 7 dage.
Partially used tablets to be used within 7 days.
Rester fra selamectin-behandlede kæledyr dræber loppeæg og larver, der ikke tidligere har været udsat for selamectin og således kan eksisterende lopprangreb fra dyrets omgivelser kontrolleres.
Debris from selamectin- treated pets kills flea eggs and larvae not previously exposed to selamectin and thus may aid in the control of existing environmental flea infestations in areas to which the animal has access.
Resterende dele af delte dispergible tabletter kan opbevares ved stuetemperatur og bør anvendes inden for 7 dage.
The remaining parts of a divided dispersible tablet can be stored at room temperature and should be used within 7 days.
Resterende dele af en delt dispergibel tablet kan opbevares ved stuetemperatur og bør anvendes inden for 7 dage.
Remaining parts of a divided dispersible tablet can be stored at room temperature and should be used within 7 days.
Resterende halve tabletter bør lægges tilbage enten i det anbrudte blisterkort i den originale æske af karton eller HDPE-flaske, og opbevares i højst 3 dage.
Any remaining half tablet should be placed back in the opened blister and stored in the original cardboard carton, or in the HDPE bottle (for a maximum of 3 days).
Resterende Nplate i hætteglasset må ALDRIG genbruges til en anden injektion.
Left over Nplate in the vial must NEVER be re-used for another injection.
Restinsulinskalaen på den gennemsigtige insulinbeholder viser hvor meget insulin der ca. er tilbage i Optiset.
The residual insulin scale on the transparent insulin reservoir shows approximately how much insulin remains in the OptiSet.
Restinsulinskalaen på den gennemsigtige insulinbeholder viser hvor meget insulin, der ca. er tilbage i OptiSet.
The residual insulin scale on the transparent insulin reservoir shows approximately how much insulin remains in the OptiSet.
Restinsulinskalaen på den gennemsigtige insulinbeholder viser, hvor meget insulin der ca. er tilbage i OptiSet.
The residual insulin scale on the transparent insulin reservoir shows approximately how much insulin remains in the OptiSet.
Restinsulinskalaen på den gennemsigtige insulinbeholder viser, hvor meget insulin, der ca. er tilbage i OptiSet.
The residual insulin scale on the transparent insulin reservoir shows approximately how much insulin remains in the OptiSet.
Restituering defineres som en stigning i den/de hæmatologiske parameter/parametre, hvor hæmatologisk toksicitet blev observeret på mindst halvdelen af forskellen mellem nadirtallet og baseline-tallet plus nadirtallet (dvs. den hæmatologiske parameter ved restituering ≥ nadirtallet + (0,5 x [baseline-tallet – nadirtallet]).
Recovery is defined as an increase of cell line(s) where haematological toxicity was observed of at least half of the difference of nadir and the baseline count plus the nadir count (i.e. blood count at recovery ≥ nadir count + (0.5 x [baseline count – nadir count]).
Restituering* ≤ 21 dage
Recovery* ≤ 21 days
Restless leg syndrom*
Restless leg syndrome